Clinical Trials Directory

Trials / Completed

CompletedNCT01174693

Comparison of Triflusal and Clopidogrel in Secondary Prevention of Stroke Based on the Genotyping

Comparison of Triflusal and Clopidogrel Effect in Secondary Prevention of Stroke Based on the Cytochrome P450 2C19 Genotyping

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
795 (actual)
Sponsor
Gangnam Severance Hospital · Academic / Other
Sex
All
Age
20 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to compare the preventive effect of stroke between triflusal and clopidogrel in ischemic stroke patient based on the cytochrome P450 2C19 (CYP2C19) polymorphism.

Detailed description

Clopidogrel has anti-platelet activity by irreversible inhibition of the P2Y12 platelet receptor. Clopidogrel must be converted into an active metabolite in order to show anti-platelet activity. Hepatic CYP2C19 enzyme is one of the key hepatic enzymes which convert clopidogrel into active metabolite and its genetic polymorphism is related to clopidogrel resistance. CYP2C19 poor or intermediate metabolizer groups show reduced anti-platelet activity of clopidogrel compared to extensive metabolizer group. This study is designed to prove the superiority of the triflusal in preventing recurrent stroke over the clopidogrel in ischemic stroke patient with poor or intermediate metabolizer of CYP2C19 polymorphism. Also we plan to prove that clopidogrel resistance is related to CYP2C19 polymorphism by comparing the ischemic preventive effect of clopidogrel between groups of different CYP2C19 polymorphism.

Conditions

Interventions

TypeNameDescription
DRUGTriflusalDose: 150mg or 300mg capsule, 300mg bid, Mode of administration: oral, Duration: from randomization to 31 December 2014
DRUGClopidogrelDose: 75mg tablet, 75mg once daily, Mode of administration: oral, Duration: from randomization to 31 December 2014

Timeline

Start date
2010-03-01
Primary completion
2014-12-01
Completion
2015-03-01
First posted
2010-08-04
Last updated
2015-03-17

Locations

18 sites across 1 country: South Korea

Source: ClinicalTrials.gov record NCT01174693. Inclusion in this directory is not an endorsement.